Fragile X syndrome medical therapy

Revision as of 15:23, 27 August 2012 by Vishnu Vardhan Serla (talk | contribs) (Created page with "__NOTOC__ {{Fragile X syndrome}} {{CMG}} == Overview == == Treatment and current research == Recent studies have focused on a number of critical areas. The role of FMRP'...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Fragile X syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fragile X syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fragile X syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fragile X syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fragile X syndrome medical therapy

CDC on Fragile X syndrome medical therapy

Fragile X syndrome medical therapy in the news

Blogs on Fragile X syndrome medical therapy

Directions to Hospitals Treating Fragile X syndrome

Risk calculators and risk factors for Fragile X syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Treatment and current research

Recent studies have focused on a number of critical areas. The role of FMRP's RNA partners, many of which have now been validated through in vitro assays, is of primary importance. Also being examined is the function the various domains of FMRP, an RNA-binding protein, which is still relatively unknown. One hypothesis is that many symptoms are caused by unchecked activation of mGluR5, a metabotropic glutamate receptor, which was found in a 2007 study to contribute significantly to the pathogenesis of the disease;[1] this suggests that mGluR5 blockers could be used to treat fragile X syndrome.[2]

While there is no current cure for the syndrome, there is hope that further understanding of its underlying causes would lead to new therapies. Currently, the syndrome can be treated through behavioral therapy, special education, medication, and when necessary, treatment of physical abnormalities. Persons with the fragile X syndrome in their family histories are advised to seek genetic counseling to assess the likelihood of having children who are affected, and how severe any impairments may be in affected descendants.

Researchers at the Picower Institute for Learning and Memory at MIT have reversed symptoms of mental retardation and autism in mice.[3]

References

  1. Dölen G, Osterweil E, Rao BS; et al. (2007). "Correction of fragile X syndrome in mice". Neuron. 56 (6): 955–62. doi:10.1016/j.neuron.2007.12.001. PMID 18093519.
  2. Highfield R (2007-12-19). "Fragile X study offers hope for autism treatment". Daily Telegraph. Retrieved 2007-12-22.
  3. MIT researchers reverse symptoms in mice of leading inherited cause of mental retardation

Template:WH

Template:WS